AlloMap Molecular Expression Testing

New from XDx – Announcing…

AlloMap molecular expression testing is now available for cardiac transplants as early as 2 months post cardiac transplant!

For cardiac transplant patients, acute cellular rejection is most worrisome in the first months post transplant. As of Monday, August 21, 2006, AlloMap molecular expression testing is available to help you monitor patients as early as 2 months post cardiac transplant. When combined with patient assessment, AlloMap testing can provide the confidence you need to rule out acute cellular rejection.

Freedom from Future Rejection

A CARGO sub-study showed that patients with scores < 20 in the first 6 months post transplant were free from ACR ≥ 3A(2R) for the next 80 days (~12 weeks)¹.

¹ Data on File

Transplant Clinic

Patients & Families

Lab Professionals

Discover XDx

Clinical Labs

Font Size:

	AlloMap Testing Overview
	AlloMap Testing Process
	Order Supplies
	AlloMap Sample Preparation Training
	Billing

XDx Reference Laboratory Certification Information

Lab Directors:
Patrick Joseph, MD
Judith Wilber, PhD, D(ABMM)

CLIA Number: 05D1029609

California License
(CLF) Number: 332008

Billing for AlloMap Molecular Expression Testing

In most circumstances, XDx bills the patient's insurer directly. Accordingly, the medical institution where AlloMap testing is ordered or the patient will not have financial responsibility for the test.

XDx bills the medical center only under the following circumstances:

When the test ordered is within the case rate period (agreed upon between the insurer and the medical center)

When the test ordered is for an inpatient with Medicare coverage

When the medical center policy is to bill all insurers directly for tests

When the medical facility providing service is also the insurer